Study results suggest that atrasentan.

11 percent in placebo A statistically significant proportion of subjects achieved >40 percent reduction in UACR from baseline in the 0.75 mg group vs. Placebo . The proportion of patients in the 0.25 mg and 1.75 mg groups didn’t reach statistical significance. Peripheral edema was the most common adverse event ‘Several huge clinical trials with RAS inhibitors possess demonstrated that reductions in albuminuria are associated with a delay in the progression of diabetic nephropathy,’ stated Donald E. Kohan, M.D., Ph.D., Professor of Medication, Division of Nephrology, University of Utah Health Sciences Center, Salt Lake City, Utah and lead investigator for the study. ‘These study email address details are encouraging and suggest that atrasentan may possess an additional therapeutic function for albuminuria reduction along with the current standard of care for patients with type 2 diabetes.’ ‘The impact of persistent kidney disease is an evergrowing global public health concern but few developments in treatment have been manufactured in the last decade that positively impact outcomes for patients with this progressive disease,’ said James Stolzenbach, Ph.D., divisional vice president, Dyslipidemia and Renal, Abbott.Natalia Rost, MD / Boston Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Illnesses Sponsored by the American Academy of Neurology, the American Academy of Neurology Basis and funded through the philanthropy of the Potamkin Family. Takeshi Iwatsubo, MD, PhD / Tokyo Neuroendocrine Research Award Sponsored by the American Academy of Neurology and supported by friends of Andrew Herzog, MD. Alison Pack, MD / New York Research Award in Geriatric Neurology Sponsored by the American Academy of Neurology and the Academy’s Geriatric Neurology Section. Gil Rabinovici, MD / SAN FRANCISCO BAY AREA Bruce S. Schoenberg International Award in Neuroepidemiology Endowed by GlaxoSmithKline, Inc. Amir Hadi Maghzi, MD / Isfahan, Iran Sleep Research Award Sponsored by the American Academy of Neurology and the Academy’s Rest Section and endowed by Cephalon, Inc.